We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+19.03%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$4.08B
AUM Growth
+$976M
Cap. Flow
+$264M
Cap. Flow %
6.47%
Top 10 Hldgs %
75.07%
Holding
69
New
11
Increased
11
Reduced
6
Closed
16
Avg Time Held Equity + Options
1.5 years
Top 10 Avg Time Held Equity + Options
2.1 years
Top 20 Avg Time Held Equity + Options
1.8 years
Avg Time Held Equity only
1.6 years
Top 10 Avg Time Held Equity only
2.1 years
Top 20 Avg Time Held Equity only
1.8 years

Top Buys

Rank Stock Value
1
BPMC icon
Blueprint Medicines
BPMC
+$97.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$85.3M
3
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$61.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$49.6M
5
RVMD icon
Revolution Medicines
RVMD
+$45.3M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$45.3M
2
KYMR icon
Kymera Therapeutics
KYMR
+$23.6M
3
ACET icon
Adicet Bio
ACET
+$20.5M
4
DYN icon
Dyne Therapeutics
DYN
+$18M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Miscellaneous 7.09%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALLO icon
26
Allogene Therapeutics
ALLO
$463M
$22.3M 0.55%
4,488,200
– –
2022 Q2
4 quarters
LENZ icon
27
LENZ Therapeutics
LENZ
$112M
$22.2M 0.54%
1,219,778
– –
2021 Q4
6 quarters
OVID icon
28
Ovid Therapeutics
OVID
$441M
$20.1M 0.49%
6,117,400
– –
2021 Q1
9 quarters
NGM
29
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$16.7M 0.41%
6,435,518
– –
2022 Q1
5 quarters
TNGX icon
30
Tango Therapeutics
TNGX
$3.83B
$13.4M 0.33%
4,047,114
-154,300
-4% -$555K
2020 Q3
11 quarters
TCRX icon
31
TScan Therapeutics
TCRX
$16.2M
$12.5M 0.31%
+5,000,000
New +$13.4M
2023 Q2
0 quarters
GBIO icon
32
DELISTED
Generation Bio
GBIO
$11.3M 0.28%
204,687
+9,029
+5% +$414K
2023 Q1
1 quarter
THRD icon
33
DELISTED
Third Harmonic Bio
THRD
$10M 0.25%
2,088,780
+286,658
+16% +$1.36M
2023 Q1
1 quarter
PHAT icon
34
Phathom Pharmaceuticals
PHAT
$607M
$10M 0.25%
+700,000
New +$8.07M
2023 Q2
0 quarters
DYN icon
35
Dyne Therapeutics
DYN
$2.86B
$8.99M 0.22%
798,701
-1,523,683
-66% -$18M
2022 Q4
2 quarters
PRME icon
36
Prime Medicine
PRME
$655M
$8.79M 0.22%
600,000
– –
2022 Q4
2 quarters
ZNTL icon
37
Zentalis Pharmaceuticals
ZNTL
$212M
$8.46M 0.21%
+300,000
New +$7.2M
2023 Q2
0 quarters
JANX icon
38
Janux Therapeutics
JANX
$1.06B
$5.37M 0.13%
452,590
-3,385,896
-88% -$45.3M
2021 Q2
8 quarters
KURA icon
39
CALL
Kura Oncology
KURA
$863M
$5.29M 0.13%
+500,000
New +$5.91M
2023 Q2
0 quarters
PRLD icon
40
Prelude Therapeutics
PRLD
$258M
$5.21M 0.13%
+1,157,452
New +$6.92M
2023 Q2
0 quarters
PRQR icon
41
ProQR Therapeutics
PRQR
$205M
$4.83M 0.12%
2,980,016
+77,301
+3% +$151K
2023 Q1
1 quarter
HOOK icon
42
DELISTED
HOOKIPA Pharma
HOOK
$4.04M 0.1%
459,502
+212,153
+86% +$2.36M
2022 Q1
5 quarters
ALGS icon
43
Aligos Therapeutics
ALGS
$33.7M
$3.83M 0.09%
157,934
– –
2021 Q4
6 quarters
ALLK icon
44
DELISTED
Allakos
ALLK
$3.27M 0.08%
+748,900
New +$3.37M
2023 Q2
0 quarters
SYRE icon
45
Spyre Therapeutics
SYRE
$7.49B
$2.25M 0.06%
+200,000
New +$948K
2023 Q2
0 quarters
NUVB.WS icon
46
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$1.73M 0.04%
963,333
– –
2021 Q1
9 quarters
TPST icon
47
Tempest Therapeutics
TPST
$10.7M
$1.43M 0.04%
86,418
+7,090
+9% +$178K
2022 Q2
4 quarters
FDMT icon
48
4D Molecular Therapeutics
FDMT
$711M
$1.21M 0.03%
+66,978
New +$1.23M
2023 Q2
0 quarters
PSTX icon
49
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$1.19M 0.03%
676,296
-1,973,704
-74% -$5.04M
2022 Q3
3 quarters
NAMSW icon
50
NewAmsterdam Pharma Warrant
NAMSW
$793K 0.02%
66,665
– –
2022 Q4
2 quarters
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2023 Portfolio in Review

As of Q2 2023, EcoR1 Capital held 69 positions worth $4.08B, up 31% from $3.11B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

EcoR1 Capital deployed $264M of net new capital in Q2 2023, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Blueprint Medicines: 1,798,300 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $45.3M trimmed.

  • EcoR1 Capital's largest Q2 2023 buy was Blueprint Medicines: 1,798,300 shares worth $114M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q2 2023, an estimated $85.3M increase.
  • EcoR1 Capital's biggest Q2 2023 reduction was Janux Therapeutics, cutting an estimated $45.3M.
  • EcoR1 Capital fully exited Kymera Therapeutics in Q2 2023, selling an estimated $23.6M.
  • EcoR1 Capital's ten largest holdings make up 75% of its $4.08B portfolio in Q2 2023.
  • EcoR1 Capital opened 11 new positions and closed 16 in Q2 2023.
  • EcoR1 Capital's portfolio value rose 31% quarter-over-quarter to $4.08B.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.